Nacuity Pharmaceuticals Strengthens Scientific Advisory Board with Appointment of Nancy Holekamp, MD, and Richard L. Lindstrom, MD

Nacuity Pharmaceuticals announced the expansion of its Scientific Advisory Board (SAB) with the appointment of Nancy Holekamp, MD, and Richard L. Lindstrom, MD.

“We are thrilled and grateful to welcome two world-renowned ophthalmologists who bring to our SAB significant and essential clinical and research expertise,” Halden Conner, Chairman, CEO, and Co-Founder of Nacuity Pharmaceuticals, said in a company news release. “As we advance our two lead clinical programs—NPI-001 for retinitis pigmentosa associated with Usher syndrome and NPI-002 to slow the progression of cataracts—currently in phase 1/2 studies, we will greatly benefit from Drs. Holekamp and Lindstrom’s decades of directly related experience.”

Dr. Holekamp is Director of Retina Services at Pepose Vision Institute in Chesterfield, Missouri. Prior to that, she was Professor of Clinical Ophthalmology and Visual Sciences at the Washington University School of Medicine in St. Louis, Missouri. 

A board-certified ophthalmologist and internationally recognized leader in corneal, cataract, refractive and laser surgery, Dr. Lindstrom is Founder and Attending Surgeon Emeritus at Minnesota Eye Consultants, Senior Lecturer and Foundation Trustee Emeritus, University of Minnesota, Board Member: University of Minnesota Foundation, and Visiting Professor: UC Irvine Gavin Herbert Eye Institute.